- Home
- SGLY vs INDP Comparison
SGLY vs INDP Comparison
Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- INDP
- Stock Information
- Founded
- SGLY 2001
- INDP 2000
- Country
- SGLY United States
- INDP United States
- Employees
- SGLY N/A
- INDP N/A
- Industry
- SGLY
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- INDP Health Care
- Exchange
- SGLY Nasdaq
- INDP Nasdaq
- Market Cap
- SGLY 3.9M
- INDP 6.0M
- IPO Year
- SGLY 2008
- INDP N/A
- Fundamental
- Price
- SGLY $1.02
- INDP $11.11
- Analyst Decision
- SGLY
- INDP Strong Buy
- Analyst Count
- SGLY 0
- INDP 2
- Target Price
- SGLY N/A
- INDP $8.50
- AVG Volume (30 Days)
- SGLY 55.8K
- INDP 692.4K
- Earning Date
- SGLY 08-26-2025
- INDP 08-11-2025
- Dividend Yield
- SGLY N/A
- INDP N/A
- EPS Growth
- SGLY N/A
- INDP N/A
- EPS
- SGLY N/A
- INDP N/A
- Revenue
- SGLY $2,172,036.00
- INDP N/A
- Revenue This Year
- SGLY N/A
- INDP N/A
- Revenue Next Year
- SGLY N/A
- INDP N/A
- P/E Ratio
- SGLY N/A
- INDP N/A
- Revenue Growth
- SGLY N/A
- INDP N/A
- 52 Week Low
- SGLY $0.54
- INDP $7.56
- 52 Week High
- SGLY $7.65
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- SGLY 50.93
- INDP 51.26
- Support Level
- SGLY $0.93
- INDP $9.45
- Resistance Level
- SGLY $1.15
- INDP $11.71
- Average True Range (ATR)
- SGLY 0.08
- INDP 2.10
- MACD
- SGLY -0.01
- INDP 0.16
- Stochastic Oscillator
- SGLY 39.13
- INDP 28.75
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.